111
Participants
Start Date
September 2, 2010
Primary Completion Date
July 4, 2013
Study Completion Date
April 5, 2018
Lenalidomide
Lenalidomide 25 mg orally for 21/28 days until Diffuse Large B-Cell Lymphoma (DLBCL) progressive disease. For patients with Creatinine Clearance ≥ 30 mL/min but \< 60 mL/min, lenalidomide 10 mg (max escalation is 15 mg).
Gemcitabine
Suggested starting doses and regimens for Gemcitabine is 1,250 mg/m\^2 intravenous (IV) administration on days 1, 8, 15 every 28 days for 6 Cycles or 1,000 mg/m\^2 IV days 1 and 15 every 28 days for 6 Cycles
Oxaliplatin
Suggested starting dose and regimen for Oxaliplatin is 100 mg/m\^2 IV day 1 for 21 days for 6 Cycles
Rituximab
Suggested starting dose for Rituximab is 375 mg/m\^2 IV days 1, 8, 15, 22 during Cycle 1, and if stable disease at Week 12, also on Day 1 of Cycles 4, 6, 8, and 10 (CD20+ patients only)
Etoposide
"Suggested starting doses for Etoposide are:~100 mg/m\^2 IV days 1-5 every 28 days for 6 Cycles, or 100 mg/m\^2 IV days 1-3 every 28 days for 6 Cycles, or 50 mg/m\^2 oral days 1-21 every 28 days for 6 Cycles, or 50 mg/m\^2 oral days 1-14 every 28 days for 6 Cycles, or 50 mg/m\^2 oral days 1-10 every 28 days for 6 Cycles"
Royal Brisbaine and Womens Hospital, Herston
Princess Alexandra Hospital, Woolloongabba
Royal Adelaide Hospital, Adelaide
University Hospital Hradec Kralove, Hradec Králové
Azienda Ospedaliera di Perugai Ospedale S. Maria della Miseri, Terni
Hospital Universitari Vll D' Hebron, Barcelona
Charles University, Prague
Institute Paoli-Calmette, Marsielle
Hospital Universitario Reina Sofia, Córdoba
Roswell Park Cancer Institute, Buffalo
Clinica Ematologica, A.O.U. San Martino di Genova, Genova
Center for Cancer and Blood Disorders, Bethesda
Fondazione IRCCS Policlinico San Matteo, Pavia
Hospital Costa Del Sol, Marbella
ICH CHU Brest- C.H.U. MORAVAN, Brest
Emory University, Atlanta
Complejo Hospitalario de Navarra, Pamplona
University Hospital OF Toulouse Purpan, Toulouse
CH de Orense, Ourense
MD Anderson Cancer Center Orlando, Orlando
CHRU-Hopital du Haut -Leveque, Pessac
CHU de Rennes Hopital de Pontchaillou, Rennes
Hosptial Clinico Universitario de Salamanca, Salamanca
Vanderbilt-Ingram Cancer Center, Nashville
CHU de Grenoble-Hopital Albert Michallon, Grenoble
Hattiesburg Clinic, Hattiesburg
"Istituto di Ematologica Istituto di Ematologica L.e. A. Seragnoli' Azienda Ospedaliera Universitaria Policlinico", Bologna
Hotel Dieu, Nantes
University of Michigan, Comprehensive Cancer Center, Ann Arbor
Azienda Ospedaliera Universitaria Careggi, Florence
Hopital de Brabois Adultes, Vandœuvre-lès-Nancy
Avera Cancer Institute, Sioux Falls
Northwestern University, Chicago
Rush University Medical Center, Chicago
Washington University Siteman Cancer Center, St Louis
Hôpital Saint Jean, Perpignan
Centre Hospitalier Lyon Sud, Lyon
Akademiska Sjukhuset, Uppsala
MD Anderson Houston, Houston
Universita Federico II di Napoli Nuovo Policlinico, Napoli
Chd -Vendee, La Roche-sur-Yon
Irccs/Crob, Rionero in Vulture (PZ)
Onkologiska kliniken, Umeå
Providence St Joseph Medical Center/Cancer Center, Burbank
IEO istituto Europeo di Oncologia, Miano
Innsbruck University Hospital, Innsbruck
Universitätsklinikum Salzburg, Salzburg
Medical University of Vienna, Vienna
Policlinico Tor Vergata (Universta Tor Vergata), Roma
Royal Bournemouth Hospital Haematology, Bournemouth
Royal Devon and Exeter Hospital Haematology Department, Exeter
St. James Institute of Oncology, Leeds
Royal Mardsen Hospital - Fulham (Satellite Site), London
The Christie Foundation Trust, I'st Floor, Haemotology Oncology Outpatients, Lymphoma Team, Manchester
Derrford Hospital, Plymouth
Southhampton University Hospital NHS Trust, Southhampton
Royal Mardsen NHS Foundation Trust, Sutton
Lead Sponsor
Celgene
INDUSTRY